New Targeted Therapy with a Double-Pronged Approach
A new targeted therapy approach may attack cancer on two fronts, boosting anti-tumor immune responses while also directly killing tumor cells .
T-Cells
Mimicking Fasting During Chemotherapy Enhances T Cell Activity in Preclinical Study
Fasting during chemotherapy treatment may increase the presence of cancer-killing T cells, according to recent study data.
Markers Found on Solid Tumors Are a Target for CAR T Cell Therapy
Chimeric antigen receptor (CAR) T cell therapy is now moving toward effectiveness against solid tumors, based on recent work in mouse models. CAR T cell therapy has already had successes against aggressive blood cancers.
TRAIL stops graft-vs-host disease after stem cell transplant for leukemia
T cells overexpressing the TRAIL protein destroyed graft-versus-host disease caused by stem cell transplant for leukemia and other cancers.
Reprogrammed donor cells thwart leukemia relapse
Specially treated T cells infused into high-risk and relapsed leukemia patients can prolong survival after stem cell transplantation.
Cancer vaccines self-sabotage by channeling immune attack to injection site
In vaccines that stimulate an immune system assult, T cells aimed at tumors instead find the vaccination site a more inviting target.
T-ALL leukemia found to differ between adults and children
T-cell acute lymphoblastic leukemia (T-ALL) in adults has significantly more mutations than does T-ALL in children, scientists have discovered.
Nelarabine plus chemo viable in children with T-cell ALL
Nelarabine is well tolerated and encouraging for pediatric patients with a slow early response in T-cell ALL.
Diagnosis of non-Hodgkin’s lymphoma
The non-Hodgkin’s lymphomas (NHLs) are a heterogeneous group of tumours of the lymphoid system and a relatively complex group of disorders. Presentation can be variable with many patients developing extranodal disease. The disease accounts for 4% of all cancer in the UK.
- Loading...
Loading...
Loading... 
Loading...